BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 22017778)

  • 21. Cardiac involvement with amyloidosis: mechanisms of disease, diagnosis and management.
    Marcu CB; Niessen HW; Beek AM; Brouwer WP; Robbers LF; Van Rossum AC
    Conn Med; 2011; 75(10):581-90. PubMed ID: 22216672
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interdisciplinary guidelines for diagnosis and therapy of extracerebral amyloidosis: issued by the German Society of Amyloid Diseases e. V. (www.amyloid.de)].
    Röcken C; Ernst J; Hund E; Michels H; Perz J; Saeger W; Sezer O; Spuler S; Willig F; Schmidt HH
    Med Klin (Munich); 2006 Oct; 101(10):825-9. PubMed ID: 17039325
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management.
    Hassan W; Al-Sergani H; Mourad W; Tabbaa R
    Tex Heart Inst J; 2005; 32(2):178-84. PubMed ID: 16107109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Amyloidoses].
    Ladner-Merz S; Müller-Ladner U
    Z Rheumatol; 2008 Dec; 67(8):677-82; quiz 683. PubMed ID: 19011876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk stratification and treatment of cardiac amyloidoses].
    Kristen AV; Schönland SO; Remppis A; Hegenbart U; Schnabel PA; Katus HA; Dengler TJ
    Pathologe; 2009 May; 30(3):212-8. PubMed ID: 19357849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Contribution of myocardial biopsy and immunohistochemistry to the prognostic evaluation of cardiac amyloidosis].
    Van de Walle JP; Fourcade L; Panagides D; Harle JR; Pellissier JF; Touze JE; Bory M
    Arch Mal Coeur Vaiss; 1994 Feb; 87(2):235-9. PubMed ID: 7802531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac amyloidosis.
    Kingman A; Pereira NL
    J S C Med Assoc; 2001 May; 97(5):201-6. PubMed ID: 11381776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New pathological insights into cardiac amyloidosis: implications for non-invasive diagnosis.
    Leone O; Longhi S; Quarta CC; Ragazzini T; De Giorgi LB; Pasquale F; Potena L; Lovato L; Milandri A; Arpesella G; Rapezzi C
    Amyloid; 2012 Jun; 19(2):99-105. PubMed ID: 22591238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The premortem recognition of systemic senile amyloidosis with cardiac involvement.
    Kyle RA; Spittell PC; Gertz MA; Li CY; Edwards WD; Olson LJ; Thibodeau SN
    Am J Med; 1996 Oct; 101(4):395-400. PubMed ID: 8873510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options.
    Alkhawam H; Patel D; Nguyen J; Easaw SM; Al-Sadawi M; Syed U; Zaiem F; Homsi M; Vittorio TJ
    Acta Cardiol; 2017 Aug; 72(4):380-389. PubMed ID: 28705053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Transthyretin amyloidoses].
    Magy-Bertrand N
    Rev Med Interne; 2007 May; 28(5):306-13. PubMed ID: 17316923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.
    Westermark P; Bergström J; Solomon A; Murphy C; Sletten K
    Amyloid; 2003 Aug; 10 Suppl 1():48-54. PubMed ID: 14640042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac amyloidosis presenting as ischemic heart disease. A case report and review of literature.
    Narang R; Chopra P; Wasir HS
    Cardiology; 1993; 82(4):294-300. PubMed ID: 8402756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Suspected cardiac amyloidosis - diagnostic steps for evaluation].
    Feldmann K; Hamm CW; Aßmus B
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1162-1168. PubMed ID: 32791553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertrophic cardiomyopathy and symptomatic conduction system disease in cardiac amyloidosis.
    Garg P; Gupta R; Hsi DH; Sheils LA; DiSalle MR; Woodlock TJ
    South Med J; 2006 Dec; 99(12):1390-2. PubMed ID: 17233198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe heart failure from light chain cardiomyopathy (cardiac amyloidosis).
    Hofer JF; Wimmer G
    Z Kardiol; 2003 Jan; 92(1):90-5. PubMed ID: 12545307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary cardiac amyloidosis: A case presentation.
    Przybojewski JZ; Daniels AR; Van der Walt JJ
    S Afr Med J; 1980 May; 57(19):774-80. PubMed ID: 7404015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.
    Pellikka PA; Holmes DR; Edwards WD; Nishimura RA; Tajik AJ; Kyle RA
    Arch Intern Med; 1988 Mar; 148(3):662-6. PubMed ID: 3341867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.